neostigmine has been researched along with Disease Models, Animal in 51 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sepsis strengthened the antagonistic actions of neostigmine on Roc-depressed twitch tension of the diaphragm by inhibiting the activity of AChE in the NMJ." | 7.83 | Sepsis Strengthens Antagonistic Actions of Neostigmine on Rocuronium in a Rat Model of Cecal Ligation and Puncture. ( Jin, T; Li, ST; Wang, H; Wu, J, 2016) |
| " Here we report the development of a new, minimally invasive behavioral model of abdominal pain induced by ip administration of neostigmine in mice." | 7.78 | New neostigmine-based behavioral mouse model of abdominal pain. ( Altier, C; Chapman, K; Fichna, J; Janecka, A; Lapointe, T; Storr, MA; Vergnolle, N, 2012) |
| "In addition to therapy with anticholinesterases, ephedrine is sometimes used to improve muscle strength in myasthenia gravis, with variable results." | 7.68 | Effect of ephedrine on muscle weakness in a model of myasthenia gravis in rats. ( Biewenga, JE; De Priester, JA; Molenaar, PC; Van Kempen, GT, 1993) |
| " The acetylcholinesterase inhibitor (ACHEI); neostigmine, is known clinically for its analgesic effect in the perioperative phases proving high efficacy; besides possessing anti-inflammatory properties controlling immune cells and cytokine level." | 4.02 | The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation. ( Abdel-Bary, A; El-Tahan, RA; Gowayed, MA, 2021) |
| "Sepsis strengthened the antagonistic actions of neostigmine on Roc-depressed twitch tension of the diaphragm by inhibiting the activity of AChE in the NMJ." | 3.83 | Sepsis Strengthens Antagonistic Actions of Neostigmine on Rocuronium in a Rat Model of Cecal Ligation and Puncture. ( Jin, T; Li, ST; Wang, H; Wu, J, 2016) |
| "The cerebrospinal fluid concentration of free neostigmine reached 5 μg/ml five hours after injection and remained constant until the end of the experiments." | 3.80 | Epidural administration of neostigmine-loaded nanofibers provides extended analgesia in rats. ( Hassanpour-Ezatti, M; Yosefifard, M, 2014) |
| " Here we report the development of a new, minimally invasive behavioral model of abdominal pain induced by ip administration of neostigmine in mice." | 3.78 | New neostigmine-based behavioral mouse model of abdominal pain. ( Altier, C; Chapman, K; Fichna, J; Janecka, A; Lapointe, T; Storr, MA; Vergnolle, N, 2012) |
| "3% w/v (weight of solute per volume of solution) monoethanolamine (MEA) into his lungs, causing asthma-like symptoms." | 3.75 | Effects of inhaled monoethanolamine on bronchoconstriction. ( Hayashi, I; Ide, A; Kamijo, Y; Majima, M; Soma, K; Yoshimura, K, 2009) |
| "In addition to therapy with anticholinesterases, ephedrine is sometimes used to improve muscle strength in myasthenia gravis, with variable results." | 3.68 | Effect of ephedrine on muscle weakness in a model of myasthenia gravis in rats. ( Biewenga, JE; De Priester, JA; Molenaar, PC; Van Kempen, GT, 1993) |
| "Patients with myasthenia gravis (MG) have increased tolerance to the neuromuscular blocking properties of suxamethonium (SCh) and decamethonium (C10) and exhibit a reversal of the C10-induced block by neostigmine." | 3.66 | Neuromuscular blocking properties of suxamethonium and decamethonium in normal and myasthenic rat muscle. ( Johnson, BR; Kim, YI; Sanders, DB, 1983) |
| " Electrophysiological and pharmacological changes typical of myasthenia gravis were recorded, including decremental responses to repetitive stimuli, curare sensitivity, neostigmine reversal, and posttetanic phenomena." | 3.65 | Blockade of acetylcholine receptors: a model of myasthenia gravis. ( Drachman, DB; Satyamurti, S; Slone, F, 1975) |
| "Pregnancy is associated with many functional changes of the urinary bladder." | 1.51 | Effect of pregnancy on the cholinergic responses of the bladder: role of acetylcholinesterase. ( Mustafa, S, 2019) |
| "In 2-month-old mice, no β-amyloid plaques deposition, but the presence of soluble oligomers, were found in CA1 area but not in dentate gyrus (DG)." | 1.42 | Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. ( Borsello, T; Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Ghiglieri, V; Sclip, A; Tantucci, M; Tozzi, A, 2015) |
| "Neostigmine treatment led to significant reduction of serum liver enzymes (LDH (47,147 ± 12,726 IU/l vs." | 1.40 | Pharmacologic cholinesterase inhibition improves survival in acetaminophen-induced acute liver failure in the mouse. ( Eisenbach, C; Hoyler, B; Mogler, C; Sandig, C; Steinebrunner, N; Stremmel, W; Vittas, S, 2014) |
| "On the other hand, in the presence of neuropathic pain, atropine (300 μg) did not alter the nociceptive threshold induced by constriction of the sciatic nerve." | 1.37 | Peripheral control of inflammatory but not neuropathic pain by endogenous cholinergic system. ( Alves, DP; Duarte, ID; Motta, PG; Perez, AC, 2011) |
| "The oral LD50 of crude Entada phaseoloides, No." | 1.36 | [Study on acute toxicity and animal gastrointestinal activity of crude and processed products of Entada phaseoloides]. ( Deng, XK; Mei, ZN; Xiao, E; Xiong, H; Zhao, YH, 2010) |
| "Treatment with physostigmine significantly reduced lethality (p < or = ." | 1.35 | Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. ( Bierhaus, A; Bode, K; Brueckmann, M; Dalpke, AH; Eisenbach, C; Encke, J; Hofer, S; Krammer, PH; Lukic, IK; Martin, E; Mautner, S; Nawroth, PP; Schneider, L; Stremmel, W; Weigand, MA; Wente, MN; Werner, J, 2008) |
| "The present study compares postoperative pain scores in male and female rats and how they respond to analgesic interventions." | 1.32 | Postoperative pain and analgesic responses are similar in male and female Sprague-Dawley rats. ( Buvanendran, A; Kroin, JS; Nagalla, SK; Tuman, KJ, 2003) |
| "Myasthenia gravis is caused by an autoimmune attack to acetylcholine receptors of skeletal muscle." | 1.30 | Acetylcholinesterase activity of skeletal muscle in a non-immunogenic model for myasthenia gravis in rats. ( Molenaar, PC; Trip, SA; Van Kempen, GT, 1999) |
| "There was an increased incidence of delayed hypersensitivity and circulating thymus antibodies in the immunized guinea-pigs and an increased incidence of thymitis in the immunized guinea-pigs and rats." | 1.25 | An investigation of experimental myasthenia gravis. ( Brennan, JL; Jones, SF; McLeod, JG, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (27.45) | 18.7374 |
| 1990's | 6 (11.76) | 18.2507 |
| 2000's | 9 (17.65) | 29.6817 |
| 2010's | 18 (35.29) | 24.3611 |
| 2020's | 4 (7.84) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Hashimoto, K | 1 |
| Tashima, K | 1 |
| Imai, T | 1 |
| Matsumoto, K | 1 |
| Horie, S | 1 |
| Gowayed, MA | 1 |
| Abdel-Bary, A | 1 |
| El-Tahan, RA | 1 |
| Margalef, R | 1 |
| Sisquella, M | 1 |
| Bosque, M | 1 |
| Romeu, C | 1 |
| Mayoral, O | 1 |
| Monterde, S | 1 |
| Priego, M | 1 |
| Guerra-Perez, R | 1 |
| Ortiz, N | 1 |
| Tomàs, J | 1 |
| Santafe, MM | 1 |
| Mustafa, S | 2 |
| Antunes, GL | 1 |
| Silveira, JS | 1 |
| Kaiber, DB | 1 |
| Luft, C | 1 |
| da Costa, MS | 1 |
| Marques, EP | 1 |
| Ferreira, FS | 1 |
| Breda, RV | 1 |
| Wyse, ATS | 1 |
| Stein, RT | 1 |
| Pitrez, PM | 1 |
| da Cunha, AA | 1 |
| Schneider, L | 2 |
| Jabrailova, B | 1 |
| Soliman, H | 1 |
| Hofer, S | 2 |
| Strobel, O | 1 |
| Hackert, T | 1 |
| Büchler, MW | 1 |
| Werner, J | 2 |
| Zhou, JX | 1 |
| Ke, P | 1 |
| Huan, G | 1 |
| Shao, BZ | 1 |
| Liu, C | 1 |
| Gotkine, M | 1 |
| Marc, G | 1 |
| Rozenstein, L | 1 |
| Leah, R | 1 |
| Einstein, O | 1 |
| Ofira, E | 1 |
| Abramsky, O | 1 |
| Oded, A | 1 |
| Argov, Z | 1 |
| Zohar, A | 1 |
| Rosenmann, H | 1 |
| Hanna, R | 1 |
| Tozzi, A | 2 |
| Sclip, A | 1 |
| Tantucci, M | 2 |
| de Iure, A | 1 |
| Ghiglieri, V | 2 |
| Costa, C | 2 |
| Di Filippo, M | 2 |
| Borsello, T | 1 |
| Calabresi, P | 2 |
| Steinebrunner, N | 1 |
| Mogler, C | 1 |
| Vittas, S | 1 |
| Hoyler, B | 1 |
| Sandig, C | 1 |
| Stremmel, W | 2 |
| Eisenbach, C | 2 |
| Yosefifard, M | 1 |
| Hassanpour-Ezatti, M | 1 |
| Ismael, HN | 1 |
| Qian, J | 1 |
| Zhang, JM | 1 |
| Lin, LL | 1 |
| Dong, WZ | 1 |
| Cheng, YQ | 1 |
| Su, DF | 1 |
| Liu, AJ | 1 |
| Martin-Flores, M | 1 |
| Paré, MD | 1 |
| Campoy, L | 1 |
| Gleed, RD | 1 |
| Wu, J | 1 |
| Jin, T | 1 |
| Wang, H | 1 |
| Li, ST | 1 |
| Kamijo, Y | 1 |
| Hayashi, I | 1 |
| Ide, A | 1 |
| Yoshimura, K | 1 |
| Soma, K | 1 |
| Majima, M | 1 |
| Kim, HN | 1 |
| Park, JH | 1 |
| Kim, SK | 1 |
| Sun, B | 1 |
| Koo, S | 1 |
| Choi, SM | 1 |
| Bae, H | 1 |
| Min, BI | 1 |
| Picconi, B | 1 |
| Cipriani, S | 1 |
| Belcastro, V | 1 |
| Xiao, E | 1 |
| Xiong, H | 1 |
| Zhao, YH | 1 |
| Deng, XK | 1 |
| Mei, ZN | 1 |
| Motta, PG | 1 |
| Perez, AC | 1 |
| Alves, DP | 1 |
| Duarte, ID | 1 |
| Zhu, H | 1 |
| Bhattacharyya, BJ | 1 |
| Lin, H | 1 |
| Gomez, CM | 1 |
| Fichna, J | 1 |
| Lapointe, T | 1 |
| Chapman, K | 1 |
| Janecka, A | 1 |
| Vergnolle, N | 1 |
| Altier, C | 1 |
| Storr, MA | 1 |
| Kroin, JS | 1 |
| Buvanendran, A | 1 |
| Nagalla, SK | 1 |
| Tuman, KJ | 1 |
| Baek, YH | 1 |
| Choi, DY | 1 |
| Yang, HI | 1 |
| Park, DS | 1 |
| Akinci, SB | 1 |
| Ulu, N | 1 |
| Yondem, OZ | 1 |
| Firat, P | 1 |
| Guc, MO | 1 |
| Kanbak, M | 1 |
| Aypar, U | 1 |
| Meekins, GD | 1 |
| Carter, GT | 1 |
| Emery, MJ | 1 |
| Weiss, MD | 1 |
| Lukic, IK | 1 |
| Bode, K | 1 |
| Brueckmann, M | 1 |
| Mautner, S | 1 |
| Wente, MN | 1 |
| Encke, J | 1 |
| Dalpke, AH | 1 |
| Nawroth, PP | 1 |
| Martin, E | 1 |
| Krammer, PH | 1 |
| Bierhaus, A | 1 |
| Weigand, MA | 1 |
| Johnson, BR | 1 |
| Kim, YI | 1 |
| Sanders, DB | 2 |
| Ruwart, MJ | 1 |
| Klepper, MS | 1 |
| Rush, BD | 1 |
| Kryzhanovskiĭ, GN | 2 |
| Atadzhanov, MA | 2 |
| Voronina, TA | 2 |
| Nerobkova, LN | 2 |
| Molenaar, PC | 3 |
| Van Kempen, GT | 3 |
| Biewenga, JE | 1 |
| De Priester, JA | 1 |
| Geddes, LA | 1 |
| Hinds, M | 1 |
| Babbs, CF | 1 |
| Tacker, WA | 1 |
| Schoenlein, WE | 1 |
| Elabbady, T | 1 |
| Saeed, M | 1 |
| Bourland, JD | 1 |
| Ayers, GM | 1 |
| Chiari, AI | 1 |
| Eisenach, JC | 1 |
| Trip, SA | 1 |
| Kobayashi, S | 1 |
| Ikeda, K | 1 |
| Suzuki, M | 1 |
| Yamada, T | 1 |
| Miyata, K | 1 |
| Miranda, HF | 1 |
| Sierralta, F | 1 |
| Pinardi, G | 1 |
| Nastuk, WL | 1 |
| Niemi, WD | 1 |
| Alexander, JT | 1 |
| Chang, HW | 1 |
| Nastuk, MA | 1 |
| Drachman, DB | 2 |
| Kao, I | 1 |
| Pestronk, A | 1 |
| Toyka, KV | 1 |
| Engel, AG | 1 |
| Tsujihata, M | 1 |
| Lindstrom, JM | 2 |
| Lennon, VA | 2 |
| Seybold, ME | 1 |
| Satyamurti, S | 1 |
| Slone, F | 1 |
| Schleifer, LS | 1 |
| Eldefrawi, ME | 1 |
| Cobb, EE | 1 |
| Johns, TR | 1 |
| Jones, SF | 1 |
| Brennan, JL | 1 |
| McLeod, JG | 1 |
| Bicks, RO | 1 |
| Bale, GF | 1 |
| Goldenberg, J | 1 |
| Rosenberg, EW | 1 |
| Hodgson, I | 1 |
| Hodgson, WJ | 1 |
| Hodgson, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension[NCT02543658] | Phase 2 | 80 participants (Actual) | Interventional | 2015-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Days in hospital within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | days (Median) |
|---|---|
| Neostigmine | 20 |
| Conservative Treatment | 19 |
Days in ICU within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | days (Median) |
|---|---|
| Neostigmine | 12 |
| Conservative Treatment | 12 |
Death during from randomization to 90 days after onset. (NCT02543658)
Timeframe: From randomization to 90 days after onset.
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 10 |
| Conservative Treatment | 11 |
Medical expenses within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | thousand(RMB) (Median) |
|---|---|
| Neostigmine | 95.3 |
| Conservative Treatment | 102.3 |
Abdominal compartment syndrome is defined as a sustained IAP>20 mmHg (with or without an APP<60 mmHg) that is associated with new organ dysfunction/failure (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 2 |
| Conservative Treatment | 4 |
Incidence of organ failure from randomization to discharge or death, assessed up to 3 months (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 12 |
| Conservative Treatment | 16 |
Due to that neostigmine has an inhibitory effect on the cardiovascular system, new-onset cardiovascular failure after grouping is considered as a possible adverse event related to neostigmine.Cardiovascular failure was defined as circulatory systolic blood pressure <90 mm Hg, despite adequate fluid resuscitation, or need for inotropic catecholamine support (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 8 |
| Conservative Treatment | 4 |
IAP rebound ≥ 5mmHg or increase ≥ 20mmHg within 1-7 days after grouping (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 4 |
| Conservative Treatment | 8 |
From date of randomization to enteral nutrition, assessed up to 30 days (NCT02543658)
Timeframe: Start time of enteral nutrition after randomization, assessed up to 30 days
| Intervention | days (Median) |
|---|---|
| Neostigmine | 3 |
| Conservative Treatment | 4 |
Monitor the intra-abdominal pressure within 1 to 7 days after randomization, and calculate the percent change compared with that before randomization (NCT02543658)
Timeframe: From randomization to 7 days after treatment,Measured IAP every 6 hours
| Intervention | percent change of IAP (Median) | |
|---|---|---|
| percent change of IAP at 24 hours | percent change of IAP at 7 days | |
| Conservative Treatment | -5.4 | -20.0 |
| Neostigmine | -18.7 | -27.2 |
After randomization, the change of stool volume (ML) was calculated every 24 hours.For example, the amount of stool volume decreased or increased in 24 hours after grouping compared to before grouping. (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | ml/day (Median) | |
|---|---|---|
| The change of stool volume at 24 hours | The change of stool volume at 7th day | |
| Conservative Treatment | 60 | 370 |
| Neostigmine | 870 | 1025 |
1 review available for neostigmine and Disease Models, Animal
| Article | Year |
|---|---|
Myasthenia gravis as a receptor disorder.
Topics: Acetylcholine; Action Potentials; Animals; Binding Sites; Bungarotoxins; Curare; Disease Models, Ani | 1976 |
50 other studies available for neostigmine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
The rodent model of impaired gastric motility induced by allyl isothiocyanate, a pungent ingredient of wasabi, to evaluate therapeutic agents for functional dyspepsia.
Topics: Animals; Benzamides; Benzyl Compounds; Disease Models, Animal; Dyspepsia; Gastrointestinal Motility; | 2021 |
The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation.
Topics: Acetic Acid; Analgesia; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dic | 2021 |
Experimental myofascial trigger point creation in rodents.
Topics: Animals; Cholinesterase Inhibitors; Disease Models, Animal; Male; Mice; Myofascial Pain Syndromes; N | 2019 |
Effect of pregnancy on the cholinergic responses of the bladder: role of acetylcholinesterase.
Topics: Acetylcholinesterase; Animals; Atropine; Cholinesterase Inhibitors; Disease Models, Animal; Female; | 2019 |
Cholinergic anti-inflammatory pathway confers airway protection against oxidative damage and attenuates inflammation in an allergic asthma model.
Topics: Animals; Asthma; Cholinesterase Inhibitors; Disease Models, Animal; Female; Inflammation; Mice; Mice | 2020 |
Pharmacological cholinergic stimulation as a therapeutic tool in experimental necrotizing pancreatitis.
Topics: Animals; Cholinergic Agents; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Glycodeoxych | 2014 |
Combined treatment with anisodamine and neostigmine inhibits joint inflammation in collagen-induced arthritis mice.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Collagen; Disease Models, Animal; Drug T | 2014 |
Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice.
Topics: Acetylcholinesterase; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Disease Progre | 2013 |
Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease.
Topics: Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Pro | 2015 |
Pharmacologic cholinesterase inhibition improves survival in acetaminophen-induced acute liver failure in the mouse.
Topics: Acetaminophen; Acetylcysteine; Alanine Transaminase; Analgesics, Non-Narcotic; Animals; Chemical and | 2014 |
Epidural administration of neostigmine-loaded nanofibers provides extended analgesia in rats.
Topics: Analgesics; Animals; Behavior, Animal; Chemistry, Pharmaceutical; Cholinesterase Inhibitors; Delayed | 2014 |
Reactivity of diabetic urinary bladder to the cholinesterase inhibitor neostigmine.
Topics: Animals; Cholinesterase Inhibitors; Diabetes Mellitus, Experimental; Disease Models, Animal; Electri | 2014 |
A combination of neostigmine and anisodamine protects against ischemic stroke by activating α7nAChR.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Cell Line, Transformed; Cytokines; Disease | 2015 |
Neuromuscular blocking effects of cisatracurium and its antagonism with neostigmine in a canine model of autosomal-recessive centronuclear myopathy.
Topics: Anesthesia Recovery Period; Anesthesia, General; Animals; Atracurium; Cholinesterase Inhibitors; Dis | 2015 |
Sepsis Strengthens Antagonistic Actions of Neostigmine on Rocuronium in a Rat Model of Cecal Ligation and Puncture.
Topics: Acetylcholinesterase; Androstanols; Animals; Cecum; Cholinesterase Inhibitors; Diaphragm; Disease Mo | 2016 |
Effects of inhaled monoethanolamine on bronchoconstriction.
Topics: Aerosols; Air Pollutants, Occupational; Airway Obstruction; Airway Resistance; Animals; Asthma; Atro | 2009 |
Electroacupuncture potentiates the antiallodynic effect of intrathecal neostigmine in a rat model of neuropathic pain.
Topics: Animals; Cholinesterase Inhibitors; Combined Modality Therapy; Disease Models, Animal; Electroacupun | 2008 |
Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome.
Topics: Animals; Cholinesterase Inhibitors; Corpus Striatum; Disease Models, Animal; Down Syndrome; Long-Ter | 2010 |
[Study on acute toxicity and animal gastrointestinal activity of crude and processed products of Entada phaseoloides].
Topics: Animals; Anti-Inflammatory Agents; Atropine; Disease Models, Animal; Drugs, Chinese Herbal; Fabaceae | 2010 |
Peripheral control of inflammatory but not neuropathic pain by endogenous cholinergic system.
Topics: Animals; Atropine; Carrageenan; Cholinergic Agents; Cholinesterase Inhibitors; Dinoprostone; Disease | 2011 |
Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals.
Topics: Action Potentials; Animals; Boron Compounds; Calcium; Calcium Signaling; Calpain; Carbachol; Caspase | 2011 |
New neostigmine-based behavioral mouse model of abdominal pain.
Topics: Abdominal Pain; Animals; Disease Models, Animal; Male; Mice; Morphine; Neostigmine; Proto-Oncogene P | 2012 |
Postoperative pain and analgesic responses are similar in male and female Sprague-Dawley rats.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Cholinesterase Inhibito | 2003 |
Analgesic effect of electroacupuncture on inflammatory pain in the rat model of collagen-induced arthritis: mediation by cholinergic and serotonergic receptors.
Topics: Acupuncture Points; Analysis of Variance; Animals; Arthritis, Experimental; Cholinesterase Inhibitor | 2005 |
Effect of neostigmine on organ injury in murine endotoxemia: missing facts about the cholinergic antiinflammatory pathway.
Topics: Animals; Disease Models, Animal; Endotoxemia; Escherichia coli Infections; Kidney; Liver; Lung; Male | 2005 |
Axonal degeneration in the Trembler-j mouse demonstrated by stimulated single-fiber electromyography.
Topics: Action Potentials; Age Factors; Animals; Cholinesterase Inhibitors; Disease Models, Animal; DNA Muta | 2007 |
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis.
Topics: Animals; Cholinesterase Inhibitors; Cytokines; Disease Models, Animal; Female; Inflammation Mediator | 2008 |
Neuromuscular blocking properties of suxamethonium and decamethonium in normal and myasthenic rat muscle.
Topics: Animals; Autoimmune Diseases; Decamethonium Compounds; Disease Models, Animal; Electrophysiology; Mo | 1983 |
Adrenergic and cholinergic contributions to decreased gastric emptying, small intestinal transit, and colonic transit in the postoperative ileus rat.
Topics: Animals; Bethanechol Compounds; Colon; Disease Models, Animal; Gastric Emptying; Gastrointestinal Mo | 1980 |
[The characteristics of a parkinsonian syndrome induced in an experiment by a deficiency of nigrostriatal dopamine and by stimulation of the cholinergic neurons of the caudate nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholine; Animals; C | 1993 |
Effect of diazepam on muscle weakness in a model of myasthenia gravis in rats.
Topics: Animals; Bungarotoxins; Diazepam; Disease Models, Animal; Female; Lip; Male; Muscle Contraction; Mus | 1993 |
Effect of ephedrine on muscle weakness in a model of myasthenia gravis in rats.
Topics: Animals; Bungarotoxins; Disease Models, Animal; Drinking; Ephedrine; Female; Lip; Male; Muscular Dis | 1993 |
Maintenance of atrial fibrillation in anesthetized and unanesthetized sheep using cholinergic drive.
Topics: Anesthesia, General; Animals; Atrial Fibrillation; Cardiac Pacing, Artificial; Cholinergic Fibers; D | 1996 |
Intrathecal adenosine: interactions with spinal clonidine and neostigmine in rat models of acute nociception and postoperative hypersensitivity.
Topics: Adenosine; Analgesics, Non-Narcotic; Animals; Clonidine; Disease Models, Animal; Dose-Response Relat | 1999 |
Acetylcholinesterase activity of skeletal muscle in a non-immunogenic model for myasthenia gravis in rats.
Topics: Acetylcholinesterase; Animals; Bungarotoxins; Disease Models, Animal; Down-Regulation; Female; Isoen | 1999 |
Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.
Topics: Animals; Bethanechol; Cholera Toxin; Colonic Diseases, Functional; Defecation; Diarrhea; Dinoproston | 2001 |
Neostigmine interactions with non steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Diclofenac; Disease Mod | 2002 |
Myasthenia in frogs immunized against cholinergic-receptor protein.
Topics: Action Potentials; Animals; Anura; Disease Models, Animal; Edrophonium; Immunization; Muscle Hypoton | 1979 |
The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study.
Topics: Animals; Autoimmune Diseases; Cholinesterase Inhibitors; Disease Models, Animal; Female; Freund's Ad | 1976 |
Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs.
Topics: Acetylcholine; Animals; Autoantibodies; Autoimmune Diseases; Body Weight; Disease Models, Animal; El | 1975 |
Blockade of acetylcholine receptors: a model of myasthenia gravis.
Topics: Action Potentials; Animals; Curare; Disease Models, Animal; Electric Stimulation; Evoked Potentials; | 1975 |
An immunological induced defect of neuromuscular transmission in rats.
Topics: Animals; Antigens; Disease Models, Animal; Edrophonium; Female; Immunization; Myasthenia Gravis; Neo | 1975 |
[Parkinson syndrome after administration of acetylcholine into the caudate nuclei].
Topics: Acetylcholine; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Electrodes, Implanted; El | 1989 |
An investigation of experimental myasthenia gravis.
Topics: Action Potentials; Animals; Antibodies; Antigens; Cattle; Disease Models, Animal; Electromyography; | 1971 |
Delayed hypersensitivity reactions in the gastrointestinal tract. IV. Effects of chronicity, neostigmine, adjuvant, and endotoxin on the pig colon lesion.
Topics: Animals; Colon; Colostomy; Disease Models, Animal; Endotoxins; Escherichia coli; Freund's Adjuvant; | 1969 |
An animal model to study diverticular disease.
Topics: Animals; Diet; Disease Models, Animal; Diverticulum, Colon; Gastrointestinal Motility; Manometry; Ne | 1972 |
An interim report on the production of colonic diverticula in the rabbit.
Topics: Animals; Body Weight; Bread; Butter; Chloralose; Colon; Constipation; Diet; Disease Models, Animal; | 1972 |
An animal model for diverticular disease.
Topics: Animals; Diet; Disease Models, Animal; Diverticulum, Colon; Gastrointestinal Motility; Manometry; Ne | 1972 |